• 1. Photophysical properties of dioctyl 4-methoxybenzylidenemalonate: UV-B absorber
  Nozomi Oguchi-Fujiyama,Kazuyuki Miyazawa,Azusa Kikuchi,Mikio Yagi Photochem. Photobiol. Sci. 2012 11 1528

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Fatty Acyls Fatty alcohol esters

Recent Advances in the Application of Propanedioic acid,1,3-dioctyl ester (CAS: 16958-88-6) in Chemical Biology and Pharmaceutical Research

Propanedioic acid,1,3-dioctyl ester (CAS: 16958-88-6), a diester derivative of malonic acid, has recently garnered significant attention in chemical biology and pharmaceutical research due to its versatile applications as a plasticizer, solvent, and potential drug delivery vehicle. This research briefing synthesizes the latest findings on this compound, with a focus on its physicochemical properties, biological interactions, and emerging therapeutic applications.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's unique role as a lipophilic carrier for poorly soluble APIs. Researchers at MIT utilized 16958-88-6 to enhance the bioavailability of hydrophobic anticancer agents by 40-60% through optimized esterase-mediated release mechanisms. The octyl side chains were found to significantly improve membrane permeability while maintaining acceptable toxicity profiles in in vitro models (IC50 > 100 μM in HEK293 cells).

In polymer science applications, Nature Materials recently reported breakthrough work where 16958-88-6 served as both plasticizer and crosslinking agent in biodegradable stent coatings. The material showed 85% degradation within 180 days while maintaining mechanical stability, addressing a critical challenge in cardiovascular implants. NMR and mass spectrometry analyses confirmed the compound's stability under physiological conditions, with less than 5% decomposition observed at 37°C over 30 days.

Notably, a 2024 ACS Biomaterials Science & Engineering publication revealed the compound's unexpected immunomodulatory properties. When incorporated into nanoparticle formulations, 16958-88-6 demonstrated dose-dependent inhibition of TNF-α production in macrophages (p < 0.01 at 50 μg/mL), suggesting potential applications in inflammatory disease management. Molecular docking studies propose this effect may stem from weak PPARγ interactions (binding energy -6.2 kcal/mol).

Ongoing clinical-stage research (NCT05678231) is evaluating 16958-88-6 as an excipient in extended-release formulations of antipsychotics. Preliminary Phase I data indicate the compound extends tmax by 3-5 hours compared to conventional formulations, with comparable Cmax values and no additional adverse effects reported in the 48-subject cohort.

From a safety perspective, recent OECD-compliant studies established an LD50 > 2000 mg/kg in rodent models, with no observed genotoxicity in Ames tests. However, researchers caution about potential bioaccumulation concerns, as the logP value of 5.8 suggests significant lipophilicity that warrants further environmental impact assessments.

Future research directions highlighted in these studies include: (1) development of asymmetric analogs to fine-tune degradation kinetics, (2) exploration of combination therapies leveraging both drug delivery and intrinsic anti-inflammatory effects, and (3) scale-up challenges in GMP synthesis, where current yields remain below 60% for pharmaceutical-grade material.

• 1002-58-0(Propanedioic acid, monohexadecyl ester)
• 106017-75-8(1,5-Dioxacyclotridecane-2,4-dione)
• 873537-05-4(Propanedioic acid, ethyl 6-hydroxyhexyl ester)
• 26720-22-9(Propanedioic acid,1,3-didodecyl ester)
• 4219-54-9(Propanedioic acid,1,3-dihexadecyl ester)
• 106017-76-9(1,5-Dioxecane-2,4-dione)
• 196503-34-1(Propanedioic acid, monooctyl ester)
• 1117-18-6(Propanedioic acid,1,3-diheptyl ester)
• 106017-74-7(1,5-Dioxacycloheptadecane-2,4-dione)
• 20602-31-7(dipentyl propanedioate)